Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ERAS-4001 in KRAS-mutant (KRASm) solid tumors. The expected timing is based on the latest available company guidance and may change.
BOREALIS-1 trial. 6/2/25- IND clearance in May ahead of company guidance. 8/12/25- Initial monotherapy data in 2026. 11/12/25:- Ph1 mono data still guided to 2026. 01/12/26:- BOREALIS-1 dose escalation advancing; initial Ph1 monotherapy data now guided to H2 2026. 02/24/26:- US patent issued for ERAS-4001; initial Ph1 mono data still expected in H2 2026. 03/12/26:- BOREALIS-1 Ph1 mono data still expected H2 2026; expansion and combo cohorts planned 2027. 05/11/26:- BOREALIS-1 Ph1 dose escalation ongoing; preliminary monotherapy data expected H2 2026; expansion and combo cohorts planned 2027. 08/11/26:- BOREALIS-1 Ph1 monotherapy data remain expected H2 2026; expansion and combo cohorts planned 2027.
Verification
Confirm timing and program details against the company announcement or filing.